A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

Summary

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with Moderate-Severe Idiopathic Inflammatory Myopathies who have failed prior therapies. Participants will be given imvotamab through a vein (i.e., intravenously).

Timeline

Start

2024-05-29

Primary completion

2025-01-21

Completion

2025-01-21

Outcome

Outcome not reported

Stopped: “Program Discontinuation”

Drugs

Indications